Did pioglitazone actually fail in PIVENS?

Not clinically. Pioglitazone achieved 47% NASH resolution versus 21% for placebo, a result that would be considered strong in most contexts. It missed the prespecified significance threshold of p < 0.025 on the primary composite endpoint (p = 0.04) because the trial used Bonferroni correction for two active comparisons against one placebo group. Guidelines still recommend it based on these data plus confirmatory trials in diabetic patients.

Can vitamin E be used in patients with diabetes and NASH?

Current AGA guidance recommends against it. PIVENS excluded diabetic patients, and no large RCT has tested vitamin E specifically in diabetic NASH. Pioglitazone has stronger evidence in this population from the Cusi et al. 2016 trial.

How long should vitamin E or pioglitazone be continued for NASH?

No guideline specifies a treatment duration. PIVENS treated patients for 96 weeks. Some hepatologists continue indefinitely if ALT remains improved, while others reassess with imaging or biopsy at 2 years. There is no standardized stopping rule.

Does vitamin E improve liver fibrosis?

No. In PIVENS, neither vitamin E nor pioglitazone produced statistically significant fibrosis improvement at 96 weeks. These drugs target inflammation and ballooning, not collagen deposition. Patients with fibrosis-predominant disease may be better served by resmetirom.

Is 800 IU of vitamin E safe long-term?

The SELECT trial found a small increased risk of prostate cancer at 400 IU/day in healthy men. PIVENS used 800 IU/day for 96 weeks without observing malignancy, but the trial was not designed to detect cancer. The AASLD recommends discussing this risk with male patients. Hemorrhagic stroke risk is also modestly elevated at high doses.

Why don't more primary care doctors prescribe these drugs for NASH?

Several barriers exist: NASH diagnosis historically required biopsy (which primary care clinics rarely perform), guidelines tie pharmacotherapy recommendations to biopsy confirmation, and many PCPs are unfamiliar with the PIVENS data. Increasing use of noninvasive markers like FibroScan and the FIB-4 index may lower the diagnostic barrier over time.

Does pioglitazone cause weight gain in NASH patients?

Yes. In PIVENS, pioglitazone-treated patients gained an average of 4.7 kg over 96 weeks versus 0.4 kg for vitamin E. This is a consistent class effect of thiazolidinediones and a common reason patients discontinue therapy. The weight gain is partly fluid retention and partly adipose redistribution.

How does PIVENS compare to the MAESTRO-NASH trial for resmetirom?

Different populations and endpoints. PIVENS enrolled nondiabetic patients with mostly F0-F2 fibrosis and measured NAS improvement. MAESTRO-NASH enrolled patients with F2-F3 fibrosis (regardless of diabetes) and measured both NASH resolution and fibrosis improvement. Resmetirom achieved fibrosis regression, which neither PIVENS drug did. The trials are complementary rather than directly comparable.

Can pioglitazone and vitamin E be combined for NASH?

PIVENS did not test a combination arm. No large RCT has evaluated combined vitamin E plus pioglitazone versus either agent alone. Some clinicians use both off-label in refractory cases, but this practice lacks controlled evidence. The theoretical rationale (anti-inflammatory plus insulin-sensitizing effects) is reasonable but unproven.

Is PIVENS relevant now that MASH has an approved drug?

Yes. Resmetirom is approved only for F2-F3 fibrosis. Patients with MASH and F0-F1 fibrosis, the majority of the MASH population, still have no approved therapy. PIVENS remains the best evidence base for pharmacologic treatment in this group.

What PIVENS Actually Changes in Clinical Practice

Q: Can vitamin E be used in patients with diabetes and NASH?

Current AGA guidance recommends against it. PIVENS excluded diabetic patients, and no large RCT has tested vitamin E specifically in diabetic NASH. Pioglitazone has stronger evidence in this population from the Cusi et al. 2016 trial.

Q: How long should vitamin E or pioglitazone be continued for NASH?

No guideline specifies a treatment duration. PIVENS treated patients for 96 weeks. Some hepatologists continue indefinitely if ALT remains improved, while others reassess with imaging or biopsy at 2 years. There is no standardized stopping rule.

Q: Does vitamin E improve liver fibrosis?

No. In PIVENS, neither vitamin E nor pioglitazone produced statistically significant fibrosis improvement at 96 weeks. These drugs target inflammation and ballooning, not collagen deposition. Patients with fibrosis-predominant disease may be better served by resmetirom.

Q: Is 800 IU of vitamin E safe long-term?

The SELECT trial found a small increased risk of prostate cancer at 400 IU/day in healthy men. PIVENS used 800 IU/day for 96 weeks without observing malignancy, but the trial was not designed to detect cancer. The AASLD recommends discussing this risk with male patients. Hemorrhagic stroke risk is also modestly elevated at high doses.

Q: Why don't more primary care doctors prescribe these drugs for NASH?

Several barriers exist: NASH diagnosis historically required biopsy (which primary care clinics rarely perform), guidelines tie pharmacotherapy recommendations to biopsy confirmation, and many PCPs are unfamiliar with the PIVENS data. Increasing use of noninvasive markers like FibroScan and the FIB-4 index may lower the diagnostic barrier over time.

Q: Does pioglitazone cause weight gain in NASH patients?

Yes. In PIVENS, pioglitazone-treated patients gained an average of 4.7 kg over 96 weeks versus 0.4 kg for vitamin E. This is a consistent class effect of thiazolidinediones and a common reason patients discontinue therapy. The weight gain is partly fluid retention and partly adipose redistribution.

Q: How does PIVENS compare to the MAESTRO-NASH trial for resmetirom?

Different populations and endpoints. PIVENS enrolled nondiabetic patients with mostly F0-F2 fibrosis and measured NAS improvement. MAESTRO-NASH enrolled patients with F2-F3 fibrosis (regardless of diabetes) and measured both NASH resolution and fibrosis improvement. Resmetirom achieved fibrosis regression, which neither PIVENS drug did. The trials are complementary rather than directly comparable.

Q: Can pioglitazone and vitamin E be combined for NASH?

PIVENS did not test a combination arm. No large RCT has evaluated combined vitamin E plus pioglitazone versus either agent alone. Some clinicians use both off-label in refractory cases, but this practice lacks controlled evidence. The theoretical rationale (anti-inflammatory plus insulin-sensitizing effects) is reasonable but unproven.

Q: Is PIVENS relevant now that MASH has an approved drug?

Yes. Resmetirom is approved only for F2-F3 fibrosis. Patients with MASH and F0-F1 fibrosis, the majority of the MASH population, still have no approved therapy. PIVENS remains the best evidence base for pharmacologic treatment in this group.

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for What PIVENS Actually Changes in Clinical Practice Image: HealthRX.com clinical image

At a glance

| Field | Detail | |---|---| | Trial name | PIVENS (PIoglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis) | | N | 247 randomized (84 vitamin E, 80 pioglitazone, 83 placebo) | | Intervention | Vitamin E 800 IU/day or pioglitazone 30 mg/day | | Comparator | Placebo | | Duration | 96 weeks | | Primary endpoint | Improvement in NASH histology (composite: ≥2-point drop in NAS, no worsening fibrosis, resolution of steatohepatitis or borderline diagnosis on repeat biopsy) | | Key result | Vitamin E: 43% vs. placebo 19% (p = 0.001). Pioglitazone: 34% vs. placebo 19% (p = 0.04, but did not meet prespecified significance threshold of p < 0.025) | | Publication | Sanyal et al., NEJM 2010 |

Why PIVENS Still Matters in a Post-Resmetirom World

Before 2024, no FDA-approved drug existed for NASH (now called MASH under updated nomenclature). PIVENS, published in 2010, gave clinicians their two best off-label tools: vitamin E and pioglitazone. With resmetirom (Rezdiffra) approved in March 2024 for MASH with moderate-to-advanced fibrosis (F2-F3), some clinicians assume PIVENS is obsolete. It is not.

Resmetirom's label is narrow. It covers fibrosis stages F2 and F3 confirmed by biopsy or noninvasive testing. Patients with F0-F1 fibrosis, the population most analogous to PIVENS, have no approved therapy. Vitamin E and pioglitazone remain the default pharmacologic options for this group in the 2023 AASLD Practice Guidance and the 2024 EASL Clinical Practice Guidelines.

The Primary Endpoint Problem: Why Pioglitazone "Failed" on a Technicality

PIVENS used a Bonferroni-corrected significance threshold of p < 0.025 for each active arm versus placebo because two comparisons were being made against a single placebo group. Vitamin E cleared this bar (p = 0.001). Pioglitazone did not (p = 0.04).

That statistical nuance created a misleading narrative. Pioglitazone did not fail to improve liver histology. It failed to meet a threshold designed to control for multiple comparisons. On every individual histologic component, pioglitazone performed at least as well as vitamin E, and on one key secondary endpoint, resolution of steatohepatitis, pioglitazone was numerically superior: 47% versus 36% for vitamin E versus 21% for placebo (Sanyal et al., 2010).

HealthRX.com Clinical Translation Framework: Reading PIVENS Results by Endpoint

The table below separates composite and component outcomes so clinicians can match the right drug to the right treatment goal.

| Outcome | Vitamin E (n=84) | Pioglitazone (n=80) | Placebo (n=83) | Clinical note | |---|---|---|---|---| | Primary composite (≥2-pt NAS drop + no fibrosis worsening) | 43% (p = 0.001) | 34% (p = 0.04) | 19% | Vitamin E met prespecified threshold; pioglitazone did not | | Resolution of NASH | 36% | 47% | 21% | Pioglitazone numerically superior | | Steatosis improvement | 54% | 69% | 31% | Pioglitazone clearly better on fat clearance | | Lobular inflammation | 52% | 56% | 31% | Comparable between active arms | | Ballooning improvement | 50% | 48% | 28% | Comparable | | Fibrosis change | No significant improvement | No significant improvement |, | Neither drug moved fibrosis in 96 weeks | | Mean weight change | +0.4 kg | +4.7 kg |, | Weight gain is the main pioglitazone liability |

This framework reveals the core tension: pioglitazone may be the better drug for histologic resolution, but vitamin E is the easier drug to prescribe because it avoids the weight-gain conversation entirely.

Which Guidelines Actually Changed After PIVENS

AASLD (2012, updated 2023)

The 2012 AASLD-ACG-AGA joint guidelines cited PIVENS directly when recommending vitamin E 800 IU/day for nondiabetic adults with biopsy-proven NASH. The recommendation carried a "B" strength of evidence, the highest for any NASH pharmacotherapy at the time. Pioglitazone received a weaker recommendation, reflecting the primary endpoint miss.

The 2023 AASLD Practice Guidance maintained both recommendations. Vitamin E is suggested for nondiabetic patients with NASH. Pioglitazone is suggested regardless of diabetes status, an expansion beyond the PIVENS population driven by subsequent data in diabetic cohorts (notably Cusi et al., 2016).

EASL (2016, updated 2024)

EASL's 2016 Clinical Practice Guidelines recommended pioglitazone (with informed consent about off-label use) and noted vitamin E as an alternative. The 2024 update places both agents in the pre-fibrosis treatment algorithm, with resmetirom occupying the F2-F3 slot.

AGA (2022 Clinical Practice Update)

The AGA's 2022 update explicitly recommended against using vitamin E in patients with diabetes and NASH, citing insufficient evidence in that subgroup. This creates a clean decision tree: vitamin E for nondiabetic NASH, pioglitazone for NASH with or without diabetes.

Prescribing Patterns That Shifted (and Some That Should Have)

What changed

Vitamin E became standard in hepatology clinics. Before PIVENS, vitamin E use for liver disease was anecdotal. After 2010, specialty hepatology practices adopted 800 IU/day as a default for biopsy-confirmed, nondiabetic NASH with at least moderate activity.
Pioglitazone gained a liver-specific rationale. Endocrinologists had prescribed pioglitazone for insulin resistance, but PIVENS gave hepatologists a reason to initiate it themselves, particularly after the Cusi et al. trial extended results to diabetic patients.
Biopsy became a de facto requirement for treatment initiation. Because PIVENS enrolled only biopsy-proven NASH and guidelines tied their recommendations to biopsy confirmation, many clinicians refused to start vitamin E or pioglitazone without one. This created a bottleneck: patients unwilling or unable to undergo biopsy received no pharmacotherapy.

What should have changed but didn't

Primary care prescribing remains almost nonexistent. PIVENS data are 15 years old, replicated in meta-analyses, and endorsed by three major societies. Yet most NASH treatment with vitamin E or pioglitazone still originates from gastroenterology or hepatology referrals. Primary care adoption has been slow, partly because NASH diagnosis itself often requires specialty evaluation.
Duration of therapy is undefined. PIVENS ran for 96 weeks. The trial included no follow-up biopsy after drug discontinuation, and histologic benefits appeared to wane after stopping pioglitazone in other studies. No guideline specifies how long to continue either drug, leaving clinicians to improvise.

Patients Who Don't Look Like the PIVENS Population

PIVENS enrolled a specific group: nondiabetic adults ages 18+, with biopsy-proven NASH, NAS ≥5, and no cirrhosis. Applying its results to other populations requires acknowledging where the evidence thins.

Patients with type 2 diabetes

PIVENS excluded diabetic patients entirely. The Cusi et al. 2016 trial in Annals of Internal Medicine filled this gap for pioglitazone, showing 58% resolution of NASH in prediabetic/diabetic patients on pioglitazone 45 mg versus 17% on placebo. No equivalent trial exists for vitamin E in diabetic NASH, which is why the AGA recommends against it in that population.

Patients with advanced fibrosis (F3-F4)

PIVENS excluded cirrhosis. Only 12% of enrolled patients had F3 fibrosis at baseline. Neither vitamin E nor pioglitazone showed fibrosis regression in the trial. For patients with F2-F3 fibrosis, resmetirom's MAESTRO-NASH data now provide a stronger evidence base, with fibrosis improvement in 25-30% of treated patients at 52 weeks.

Pediatric patients

The TONIC trial (2011, JAMA) tested vitamin E 800 IU/day in children aged 8-17 with NAFLD. Vitamin E did not meet its primary endpoint (sustained ALT reduction) but did show significant NASH resolution on biopsy. Pediatric guidelines remain cautious, and routine use of vitamin E in children with NASH is not standard.

Men vs. women

PIVENS enrolled 56% men. Subgroup analyses were not powered for sex-based differences, and none were reported. Post-hoc data from the NASH CRN suggest women may respond slightly better to vitamin E, but this has not been confirmed prospectively.

Safety Signals That Clinicians Weigh Against Benefit

Vitamin E

The SELECT trial (2011, JAMA) reported a statistically significant increase in prostate cancer risk among healthy men taking vitamin E 400 IU/day (HR 1.17, 95% CI 1.004-1.36). PIVENS used double that dose. No increase in cancer was observed within the 96-week PIVENS trial itself, but the trial was not powered to detect malignancy. The AASLD guidelines note this concern without contraindicating use, stating the risk-benefit should be discussed with male patients.

Hemorrhagic stroke risk with high-dose vitamin E supplementation has been raised in meta-analyses. The absolute risk increase is small, but clinicians managing patients on anticoagulants should account for it.

Pioglitazone

Weight gain averaged 4.7 kg in PIVENS. In the longer Cusi trial (18 months active + 18 months open-label), weight gain reached approximately 2.5 kg above baseline at 36 months. For patients already struggling with obesity-related NASH, this creates a real compliance problem.

Fluid retention and congestive heart failure risk are class warnings for thiazolidinediones. PIVENS excluded patients with NYHA class III-IV heart failure. Pioglitazone is also associated with decreased bone mineral density, a consideration for postmenopausal women. The FDA prescribing information for pioglitazone details these risks and frames them against the metabolic benefits.

The Practical Decision Tree in 2026

For a treatment-naive patient with biopsy-proven MASH and no advanced fibrosis:

Nondiabetic, male, no prostate cancer history: Vitamin E 800 IU/day is the path of least resistance. Discuss SELECT trial signal.
Nondiabetic, female: Vitamin E 800 IU/day. Prostate cancer concern is absent.
Type 2 diabetes, any sex: Pioglitazone 30-45 mg/day, per Cusi et al. Vitamin E lacks evidence in this group.
F2-F3 fibrosis, any diabetes status: Consider resmetirom per MAESTRO-NASH. Vitamin E and pioglitazone lack fibrosis-regression data.
Unwilling to biopsy: Clinician judgment. Some practices now initiate vitamin E based on elevated ALT + imaging-confirmed steatosis + exclusion of other liver diseases, though this remains off-guideline.

Neither PIVENS drug improved fibrosis. That single fact defines the boundary of their clinical utility: they treat the inflammatory component of MASH, not the structural damage that drives liver-related mortality.

Frequently asked questions

›

References

Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685. PubMed
Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305-315. PubMed
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. PubMed
Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497-509. PubMed
Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659-1668. PubMed
Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549-1556. PubMed